XETRA - Delayed Quote EUR

Bayer Aktiengesellschaft (BAYN.DE)

26.33 +0.09 (+0.32%)
At close: 5:37 PM GMT+2
Loading Chart for BAYN.DE
DELL
  • Previous Close 26.24
  • Open 26.14
  • Bid 26.34 x 28400
  • Ask 26.35 x 2100
  • Day's Range 25.61 - 26.36
  • 52 Week Range 24.96 - 61.08
  • Volume 4,224,860
  • Avg. Volume 4,709,741
  • Market Cap (intraday) 25.862B
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) --
  • EPS (TTM) -2.99
  • Earnings Date May 14, 2024
  • Forward Dividend & Yield 0.11 (0.42%)
  • Ex-Dividend Date Apr 29, 2024
  • 1y Target Est 34.90

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

www.bayer.com

96,931

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYN.DE

Performance Overview: BAYN.DE

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BAYN.DE
21.72%
DAX PERFORMANCE-INDEX
5.88%

1-Year Return

BAYN.DE
55.33%
DAX PERFORMANCE-INDEX
11.68%

3-Year Return

BAYN.DE
45.54%
DAX PERFORMANCE-INDEX
14.73%

5-Year Return

BAYN.DE
47.28%
DAX PERFORMANCE-INDEX
45.12%

Compare To: BAYN.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYN.DE

Valuation Measures

As of 4/19/2024
  • Market Cap

    25.78B

  • Enterprise Value

    58.07B

  • Trailing P/E

    --

  • Forward P/E

    5.03

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.54

  • Price/Book (mrq)

    0.78

  • Enterprise Value/Revenue

    1.22

  • Enterprise Value/EBITDA

    5.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.17%

  • Return on Assets (ttm)

    4.04%

  • Return on Equity (ttm)

    -8.17%

  • Revenue (ttm)

    47.64B

  • Net Income Avi to Common (ttm)

    -2.94B

  • Diluted EPS (ttm)

    -2.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.59B

  • Total Debt/Equity (mrq)

    136.06%

  • Levered Free Cash Flow (ttm)

    1.52B

Research Analysis: BAYN.DE

Analyst Price Targets

25.00
34.90 Average
26.33 Current
61.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

People Also Watch